As part of our research on compulsory licensing we have now added a case study on efavirenz – the antiretroviral that Brazil needed for its public funded HIV treatment program. Brazil was forced to do so because of failure of negotiation for a voluntary license by the patent holder, Merck. This case is the first addition to a new section entitled: Case Studies in Global Health
Recent Posts
- Socially Responsible Licensing Guide for Technology Transfer Offices
- The ATP Project Holds an Expert SRL Workshop in Venice (2012)
- New publication from the ATP consortium
- New Publication on Socially Responsible Licensing Initiatives in South Africa
- New publication on R&D for Neglected Diseases from the University of Neuchâtel
Recent Comments
- roberto glasser on Compulsory licensing of an antiretroviral in Brazil
i live in brazil and a have aids and make use of drugs made in brazil like efavirenz and other the treament is wonderful the hospital emilio ribas in sp capital is wonderful i have no money and the goverment pay all this is the best thing that exist in brazil and the rest of the world may follow ,thaks for jose serra polico brasileiro who begging the generic drugs thanks for my life